🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

21 recruiting trials

for Severe Hemophilia A

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab NCT06145373Phase 43 sites📍 Los Angeles📍 Flowood📍 Taipei Sanofi · Tests: Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC),… A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B NCT06379789Phase 1, Phase 252 sites📍 Phoenix📍 Los Angeles📍 Los Angeles Regeneron Pharmaceuticals · Tests: REGV131, LNP1265 Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. NCT07437404Phase 31 site📍 Beijing Sinocelltech Ltd. · Tests: SCT800 prophylaxis and treatment for bleeding events A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B NCT05611801Phase 363 sites📍 Salt Lake City📍 Mendoza📍 Parkville Pfizer · Tests: marstacimab Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study NCT05935358Phase 418 sites📍 Dallas📍 Zagreb📍 Helsinki Octapharma · Tests: Nuwiq Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis NCT05022459n/a10 sites📍 Little Rock📍 Palo Alto📍 San Diego Wayne State University · Tests: Emicizumab, FVIII Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors NCT05145127Phase 378 sites📍 Iowa City📍 New Hyde Park📍 Philadelphia Pfizer · Tests: PF-06741086 Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project NCT07418827n/a25 sites📍 Saint-Denis📍 Annecy📍 Bordeaux Assistance Publique Hopitaux De Marseille · Tests: questionnaires A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A NCT07226206Phase 1, Phase 26 sites📍 Orange📍 San Francisco📍 Vallejo Hoffmann-La Roche · Tests: SPK-8011QQ Long-term Anticoagulation in a Patient With Severe Hemophilia A NCT07314983n/a1 site📍 Strasbourg University Hospital, Strasbourg, France A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A) NCT05981274n/a1 site📍 Taipei Tri-Service General Hospital (TSGH) · Tests: serum biomarker. ASC618 Gene Therapy in Hemophilia A Patients NCT04676048Phase 1, Phase 21 site📍 Little Rock ASC Therapeutics · Tests: ASC618 Hemophilia A Research Program NCT07414511n/a1 site📍 Seattle University of Washington Multidimensional Assessment of Chronic Pain in Severe Haemophilia A NCT07096349n/a1 site📍 Oviedo Investigación en Hemofilia y Fisioterapia A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study) NCT07582276n/a1 site📍 Little Rock Arkansas Children's Hospital Research Institute Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab NCT05802836n/a1 site📍 Frankfurt am Main Christoph Königs · Tests: no interventions A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. NCT06703606Phase 110 sites📍 La Jolla📍 La Jolla📍 Los Angeles Pfizer · Tests: MARSTACIMAB TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies NCT07692217n/a1 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A NCT05500807Phase 112 sites📍 Orange📍 Redwood City📍 Coral Gables Bleeding and Clotting Disorders Institute Peoria, Illinois · Tests: Emicizumab Liver Biopsy In Haemophilia Gene Therapy NCT04817462NA1 site📍 London University College, London · Tests: Liver biopsy A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A NCT05987449Phase 1, Phase 214 sites📍 Sacramento📍 Washington D.C.📍 Indianapolis Hoffmann-La Roche · Tests: NXT007
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy